ࡱ> / xfbjbjEE 4r/d/dL87\nr ~-//////$VS]nnS!!!R-!-!!$$`)rcX|$Ƅ0$,""$"$D_!SS " :  Activity Title:   Activity Date:  Name:   Degree(s):  Roles:  Faculty  FORMCHECKBOX  Course Director  FORMCHECKBOX  Author  FORMCHECKBOX   Reviewer  FORMCHECKBOX  Moderator  FORMCHECKBOX  Planning Committee  FORMCHECKBOX  As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Alpert Medical School of Brown University must ensure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored educational activities. Any individual being considered to participate in a sponsored activity who is in a position to control the content is required to disclose all relevant financial relationships with commercial interests. The intent of this disclosure is to aid the Continuing Medical Education Office in determining: 1) if a conflict of interest exists; and, if so, 2) if that conflict can be resolved. All such information disclosed by everyone appointed to participate in the CME activity will be conveyed to the CME activity participants. Refusal to disclose prohibits participation. *A Commercial Interest is any proprietary entity producing, marketing, reselling, or distributing health care goods or services, consumed by, or used on, patients, with the exemption of government organizations and providers of clinical service or an entity that advocates for use of products or services of commercial interest organizations. *Relevant Financial Relationships are those relationships in which an individual (including spouse/partner) has both: A personal financial relationship with a commercial interest within the past 12 months whether the relationship has ended or is currently active. This would include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g. stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. Control in planning or presenting educational content addressing specific products, agents, devices of the commercial interest (not simply a whole class of products or content about the whole disease class). ****************************************************************************** I. Do you, your spouse or legally recognized domestic partner have a financial interest (within the past 12 months) with any commercial interest that is relevant to or could impact the content included in this CME activity? NO  FORMCHECKBOX  YES  FORMCHECKBOX  II. If yes, please complete the following. (if additional space is needed, please attach) Company NameNature of Relevant Financial Relationship Non-profits and government units excludedGrant/ Research SupportConsultantMajor StockholderSpeakers BureauOther (Be Specific) 1.  FORMTEXT        FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMTEXT       I  FORMCHECKBOX  Spouse/Partner  FORMCHECKBOX  2.  FORMTEXT        FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMTEXT       I  FORMCHECKBOX  Spouse/Partner  FORMCHECKBOX  3.  FORMTEXT        FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMTEXT       I  FORMCHECKBOX  Spouse/Partner  FORMCHECKBOX  4.  FORMTEXT        FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMCHECKBOX   FORMTEXT       I  FORMCHECKBOX  Spouse/Partner  FORMCHECKBOX III. Unlabeled/Investigational Uses: Should your presentation include discussion of unlabeled/investigational use of a commercial product, you are required to disclose this to the participants. Will your presentation discuss unlabeled/investigational uses of a commercial product? NO  FORMCHECKBOX  YES  FORMCHECKBOX  If Yes, please list the unlabeled/investigational uses of any products that you plan to discuss:  IV: Content Validation / Attestation: (This section does not pertain to administrative planners not involved in content development, review, presentation. Planners may proceed to signature section) I have disclosed all relevant, or lack of, financial relationships, and I will disclose this information to learners. If I have been trained or engaged by a commercial entity or its agent as a speaker (e.g. speakers bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity. If I or my spouse/partner is an employee of a commercial interest, I will not present information on the business lines or products of my company. I understand that my presentation must be submitted for review prior to the beginning of the activity. I understand that a non-conflicted medical reviewer may need to review my presentation and/or content prior to the activity, and I will provide educational content and resources in advance as requested. I have reviewed and agree to comply with the ACCME Standards for Commercial Support, Accreditation Criteria, and Brown Universitys CME policies and procedures. All the recommendations involving clinical medicine related to my content will be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in my content in support or justification of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection and analysis. To help learners judge the quality of data provided, I will present the source and type or level of evidence (i.e. animal study, randomized controlled trial, meta-analysis, etc.). Research findings and therapeutic recommendations in my content will be based on scientifically accurate, up-to-date information and be presented in a balanced, objective manner. For any drug/product discussed, I will objectively select and present data, fairly present both favorable and unfavorable information about the drug/product, and I will include information about reasonable alternative treatment options. Where there is a suggestion of superiority of one drug/product over another, this suggestion will be supported by evidence-based data. If I am discussing specific healthcare products or services, I will use generic names to the extent possible. If I need to use trade names, I will use trade names from several companies when available, and not just trade names from any single company. I attest to compliance with all applicable laws, including copyright laws. $&'/12>?@CJSTUcd}q}bN}7,j hyh "5CJU\]aJ&jhyh "5CJU\]aJhyhD5CJ\]aJhy5CJ\]aJhyh "5CJ\]aJhyhCW5CJaJhyhCWCJ\]aJhyhCWCJaJhyhCW5CJ\]aJhyh "CJaJhyh1RhCJ\]aJhyh1RhCJaJhyh1Rh5CJaJhyh1Rh5CJ\]aJ$%&'(/01r}kd$$Ifll\fN'J  t'44 lalyty `0$*$Ifgd&1 12>?@CKLfgr}kd$$Ifll\fN'J  t'44 lalyty `0$*$Ifgd&1 degiyz{ οݨݿݑݿzc,jhyh "5CJU\]aJ,jjhyh "5CJU\]aJ,jhyh "5CJU\]aJ,jhyh "5CJU\]aJhyhD5CJ\]aJhyhEc5CJ\]aJhyh "5CJ\]aJ&jhyh "5CJU\]aJ 9kd$$Ifl֞z'>..o t'44 lalyty `0$*$Ifgd&1 - e j k m   j l Ƶtht]tRFhyh1Rh5CJaJhyhCWCJaJhyhACJaJhyhx95CJaJhyhx9CJaJhyhCWaJhyht`aJhyh "aJ hyaJhyh1RhaJhyOJQJ^JaJ hyh "56CJ\]aJhyh "5CJ\]aJ&jhyh "5CJU\]aJ,jVhyh "5CJU\]aJ j 9 *=v]$ `0PP$*$@&Ifa$gd&1$ `0dhx*$a$gd:$ `0x*$a$gd`$ `0x*$a$gdy & F `0vdd*$[$\$]vgdym$ `0vdd*$[$\$]vgdym$$ `0vx*$]va$gdx9xgdy )*/Kj   !"'(6uauP jhyh1Rh5CJUaJ&jhyhh5CJUaJ jhyhh5CJUaJhyhh5CJaJhyhm~CJaJhyh1Rh5CJaJhyhA5CJaJhyhy5CJaJhy5CJaJhyCJaJhyhhCJaJhyhx9CJaJhyh1RhCJaJhyh:5CJaJ678<AIlw&(<>ûÎÎåååðlT/jhyh1Rh5CJPJUaJmHnHu&jhyh1Rh5CJUaJhyhh56CJaJhyhh5CJaJhyhyCJaJhyh1RhCJaJhyhm~CJaJhyCJaJhyh1Rh5CJaJhyhEc5CJaJ jhyh1Rh5CJUaJ&j hyh1Rh5CJUaJ =($ `0$*$@&Ifa$gd&1kd$$Ifl4F !*  t0,    44 layt&1$ `0$*$@&If]a$gd&1$ `0PP$*$@&Ifa$gdh(>bt$ `0$*$@&Ifa$gd&1#kd/$$Ifl4֞  *!*  ...  t0,44 layt&1,.RTxz:<>npFf $ `0$*$@&Ifa$gd&1 `0$*$@&Ifgd&1 &(*.0LNPTVrtvz|mV,jhyh1RhCJPJUaJmHnHu#j hyh1RhCJUaJ#j_ hyh1RhCJUaJ#jhyh1RhCJUaJ#jshyh1RhCJUaJ#jhyh1RhCJUaJ#jhyh1RhCJUaJjhyh1RhCJUaJhyh1RhCJaJhyh1Rh5CJaJ!468:<FH\^`jlprݸݘyaM&jhyh1Rh5CJUaJ/jhyh1Rh5CJPJUaJmHnHu&jhyh1Rh5CJUaJhyhm~CJaJ&j hyh1Rh5CJUaJhyhr5CJaJ&jK hyh1Rh5CJUaJ jhyh1Rh5CJUaJhyh1Rh5CJaJhyh "5CJaJhyh1RhCJaJ &(*.0DFHRTVygP,jhyh1RhCJPJUaJmHnHu#jhyh1RhCJUaJhyh1RhCJaJjhyh1RhCJUaJ&jfhyh1Rh5CJUaJ&jhyh1Rh5CJUaJ&jzhyh1Rh5CJUaJ&jhyh1Rh5CJUaJhyh1Rh5CJaJ jhyh1Rh5CJUaJVZ `0$*$@&Ifgd&1$ `0$*$@&Ifa$gd&1VXZ^`|~۶ۢʗo[oCoo/jhyh1Rh5CJPJUaJmHnHu&jAhyh1Rh5CJUaJ jhyh1Rh5CJUaJhyh1Rh5CJaJhyhm~CJaJhyh1RhCJaJ&jhyhm~5CJUaJ&jRhyhm~5CJUaJ jhyhm~5CJUaJhyhm~5CJaJhyh`5CJaJhyhr5CJaJ$kd:$$Ifl֞  *!* ... t0,44 layt&1$&JLprXZ\Ff$ `0$*$@&Ifa$gd&1 `0$*$@&Ifgd&1 "&(DFHLNjlnrtϻϧϓpeSp#jhyh1RhCJUaJhyh1RhCJaJjhyh1RhCJUaJ&jhyh1Rh5CJUaJ&jhyh1Rh5CJUaJ&jhyh1Rh5CJUaJ&j-hyh1Rh5CJUaJhyh1Rh5CJaJ jhyh1Rh5CJUaJ&jhyh1Rh5CJUaJ  46RTVXZdfz¶qf[J jhyh1Rh5CJUaJhyhm~CJaJhyh1RhCJaJ&jhyhm~5CJUaJhyhr5CJaJ&j{hyhm~5CJUaJ jhyhm~5CJUaJhyhm~5CJaJhyh`5CJaJhyh1Rh5CJaJjhyh1RhCJUaJ,jhyh1RhCJPJUaJmHnHuz|~ "&(DFHL۷۷۷۷۷۷{۷۷g۷۷S۷&jhyh1Rh5CJUaJ&j hyh1Rh5CJUaJ&jhyh1Rh5CJUaJ&j4hyh1Rh5CJUaJ&jhyh1Rh5CJUaJhyh1Rh5CJaJ/jhyh1Rh5CJPJUaJmHnHu jhyh1Rh5CJUaJ&jHhyh1Rh5CJUaJ$&tv `0$*$@&Ifgd&1$ `0$*$@&Ifa$gd&1LNbdfprtvz|𰤘sgSH<hyhy5CJaJhyhm~CJaJ&jhyhm~5CJUaJhyhr5CJaJ&jhyhm~5CJUaJ jhyhm~5CJUaJhyhm~5CJaJhyh`5CJaJhyh1Rh5CJaJ,jhyh1RhCJPJUaJmHnHu#j hyh1RhCJUaJhyh1RhCJaJjhyh1RhCJUaJ$ (gd*!kdj $$Ifl֞  *!* ... t0,44 layt&12  5MdƺxdxXLDhyCJaJhyh]/5CJaJhyh*!5CJaJ&j!hyh`5CJUaJ jhyh`5CJUaJ&jq!hyh|5CJUaJ jhyh|5CJUaJhyh|5CJaJhyh?gnj 7!!|wwwwrrrrrrgdNbgdCWnkdY"$$Ifl\(&* t0644 lap ytC+ dh$IfgdC+dhgd| <=>?Bguv !!!!]"^"##-&.&,'-''ddddee e*ePeZe[eǻ}qqhyhNb5CJaJhC+hNbCJaJhC+hNb5CJaJhyhy5CJ\]aJUhyhNbCJaJhyhCWCJaJhyhCW5CJaJhyhy5CJaJhyh|5CJaJhC+hyCJaJhC+h|CJaJhyh|CJaJ*!"W#u$$-%%&''~ddddeee $IfgdNb $IfgdC+gdygdNb I have not and will not accept any honoraria, additional payments or reimbursements for this CME activity from a commercial entity. Your signature indicates that you have read this form in its entirety and that you agree with the statements above.  Signature (electronic signatures are acceptable) Date     Office of Continuing Medical Education Brown University, Division of Biology & Medicine G R-156, Providence, RI 02912 Phone: 401-863-3337 Fax: 401-863-2202 Email: doebaederamersa@gmail.com Disclosure of Relevant Financial Relationships Rev. 07/26/2017 e eZe[e]e^e`eaecedefegeheieke $Ifgdp (gd*!gdNbakd"$$Ifl+0A/* t*644 lapytC+[e\e^e_eaebedeeegeheiejekeeee ff*f+f,f-f\f]f^f_fafffvh\QhAh*CJaJ#h}5;>*CJOJQJ^JaJh&1h}CJOJQJaJhCJaJmH sH hAh(<CJaJmH sH hAheCJaJmH sH hAheCJaJhAh(<CJaJhAhe5CJaJh}jp#h}Uhh1@jh1@Ukeeee f+f,f-f\f]f^f_fqfrf~v$a$gd}$a$gdZH0Vkd:$$Ifl0 (v t)644 layt&1 $Ifgd(< $Ifgde 0$If]0gde ffpfqfrfsftfufwfxfhyhCW5CJaJh1@hhKDhAh}CJaJhAhCWCJaJrfsftfufvfwfxf (gd*!21h:pNb/ =!"#$% $$Ifl!vh#v#v#v#vJ :V ll t'5555J / alyty$$Ifl!vh#v#v#v#vJ :V ll t'5555J / alytyvDeCheck10vDeCheck11tDeCheck9vDeCheck12vDeCheck13vDeCheck14$$Ifl!vh#v#v#v#v>#v.#vo:V l t'5555>5.5o/ /  / / alytytDeCheck1tDeCheck1$$If!vh#v #v#v:V l4 t0,++,,5 55ayt&1$$If!vh#v #v.#v#v.#v#v:V l4 t0,++,5 5.55.55/ ayt&1vDText22vDeCheck15vDeCheck21vDeCheck27vDeCheck33vDeCheck39vDText30tDeCheck1tDeCheck2$$If!vh#v #v.#v#v.#v#v:V l  tF0,5 5.55.55/ / / apFyt&1Ukd3 $$Ifl֞  *!* ...  tF0,44 lapFyt&1vDText23vDeCheck16vDeCheck22vDeCheck28vDeCheck34vDeCheck40vDText31tDeCheck1tDeCheck2$$If!vh#v #v.#v#v.#v#v:V l t0,5 5.55.55/ / / / / ayt&1vDText24vDeCheck17vDeCheck23vDeCheck29vDeCheck35vDeCheck41vDText32tDeCheck1tDeCheck2$$If!vh#v #v.#v#v.#v#v:V l  tF0,5 5.55.55/ / / apFyt&1Ukdc$$Ifl֞  *!* ...  tF0,44 lapFyt&1vDText25vDeCheck18vDeCheck24vDeCheck30vDeCheck36vDeCheck42vDText33tDeCheck1tDeCheck2$$If!vh#v #v.#v#v.#v#v:V l t0,5 5.55.55/ / / / / ayt&1tDeCheck1tDeCheck1$$If!vh#v(:V l t065&*/  / p ytC+w$$If!vh#v#v:V l+ t*655/ pytC+]Dd > *D  3 A"`b6;z4 #qn6;z4 PNG  IHDR6UҹsRGB pHYsod-IDATx^tpPED &(bb/v{Ea 6DJPl6@QTJMr 잜{̝WgQRRRWzR1C.(}O|%\kzhݺu|9s欲*{FP -2+zzw{wuQ{9sJ+t1l'pB˖-oFO,XP8@uS ꫯ.ҟo]#G<#0e w'h۶3Ħ묳Nvvvg}FcġC(+ixѣGSOh N:իR3r5QÝ'NA&ٳioa6wܱcvmK.hO>p֭[k۸qc|_vSMNi(U4kf͚B v){^_A 6v;?<2e GFTk׮^/#[w(Pʦ#dMrrr|RaO?߿?Nuq=XxIXuUwi'̄²/³>K=SVK4rB(P؋ ?o޼~gϞ|OW\qoR:xw~>(mժ]{Rǣ*(M6MP6-{1@&Liذa)ujO?6z Y|Uf*0_@d~P@,.0UG4O(QMssΚ2iG:+ޮ͵aF.Di޼9fm۾mVrsBU@-t);'ߵ}Qfg{!}ҽ;U4b;{Ϛ9q6as٣sN#ׯm0uQ5Y N}h4O(v'@eC̓O>jo0hC}e8xG9 bQϘW#…^[KÇ7[c5c=xgwe2xРA2 dfq5s9^xM 7G,EK.zd:hr!Y!+tIKmx1GeJ(PN߳/_6TkP6V($|)uZhR۪C?^",^2n8I3)/O)5w3!+S T,(,/?L5;g:HZHj< y}x ı !兄EvQ@70(7V[mGw R"mmL0cǎp UèQ(qGgu֯hICx%Q(-z[(|>7tnFoyD\ DPߧ随<44˝BlQoBkTMC!e:[5wiơP"&#lov QPx6 Njf"I>\BHLTa-;5ټ9.[-4nX:kC9 .v%Y!< T۫JXIߙ5 񕌎0-Rb`Q9^J̑°{R'@S'Dɪp1Hbr+h пDB4rq bW&)vx&>/#9 *f+M? r|Pr~Hmȍ\O ڲE& jaitmkT~E;/Wm_"tZIdaM2R!);^d?R񧖓$t>IQ8/Z*htQ.VTI7﬚qo%Ǐ/;`޽{-؂zڋUu6j@ Q>JiU~q6}.rnJBH DcmDq&wAs`bB)X+ BlACOAE6& H ZrU+aS* ׌{b$RP^rri0cFz4\s5D` 4F dչar7J;~B:@txbY|Lhč_¤ U0K}p$WR F@뇪G3+ލȵYT~C֜wFf= 7M䛲H6tSorˎ*1bA7l"n:OOWG~*#s/FB严Ζˣ 7:ULg:MSfD䠗jQgx≶'{?czΜU;3+gƖZ'i.,$YH ӷN^Y9o⽷̬^2.~fP*8UFZ~=Ẕ)[=pڵ*7eef6Us}uVŻm^XǞ:dr%"2d XIIڙ鎊))8'%Iش/(i^J̒Z%y+ b^Ƅ HrNS h8/^FI1(Ӹɔ: ԗMAqi%%i7ו=\.:פ"ʈMGE) ?#Gp5Y*gӱEn¢"R=Y[|'|kC{a*'gY?4aK-6yo_/d§g{q9H$~뭷AyBLtIv+:ZP@|88;`8xdZjSOVw7 hb.! W/I'Gyf>h-vnsvs6ЫKxa/`_lz"G8b[rNLMkbo tHx3)a#HA,nTxl׻"3\䗄 Nr9@ڹ7L'չ[A&M$1E8ӯ{FQ~%9&}lp(r-b`Q>{Wex($zQxv|ViQx]wLЕEP>s9:F(;t`iBH23B N1Wjr*V&#bH2/mO\qn&BGfI#ΣWI!}W{F)l͊o lz P ,$Me `ܐە$*&%)-9BB=XDD:(.-e]aA!c)a3 ?m&LI jM+35`P.PRު3MC[]T/BY~XLLCQf#D ћUQH\/;IR~Ȥv5# a/^a٫H[HUMLN[.":Pq&j3!託muѱ5R(Zfa-2dxadm*3l9yr˒EZ_($orAW %No=X}qc]aYcWܹ]eK5U}˚,QTQTE:BJp> m )&K+780H ֨PeWpSZxj[NW(;OvKw=M,f 5S6*d.D_z@ΫZP뭄d.VB DԃdZy_Cf84PF&NVʽwM3[zp@8H, p{ϐmt(/ԁIFf<6 acBMBdz )'8A)@u$1týXU %;x$.|j.iHwaUuҗD #h %YQR,h*RlydymgҩpbOSE{Db YB+v$u莡'ڡ?[k}:QTk78;Z8X}nzŔ"덾5Ue[X/bH%i#Is5Mڣz> (fشa9A9}1q 5*AnvZjc &ۊh/<8$_x!u$A~aӯN=!CώA^<%hQHr 0({(^RXD!-ZRRa` ~}p8lOzLЋX_aQHfY Yofۭ!YZM:U8ɣ&ц\rO:.#K|l`4irgɊs9(*oT VfnE_ZBGƎ+ aF(O@\](0{:f~\$+Z 4XT,S[;"毭]& =ĮuZ6(&Z1ZRcS*^yzrTOsO{Kj.Xd/T䇬᨜U4P2hZZLF l)e3KSaGbQ,,(GchMu;_*jpǟw{_qB_t V7"qs*B*phPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VGRU1a$N% ʣꂣKЛjVkUDRKQj/dR*SxMPsʧJ5$4vq^WCʽ D{>̳`3REB=꽻Ut Qy@֐\.X7<:+& 0h @>nƭBVqu ѡ{5kP?O&Cנ Aw0kPo۵(h[5($=CVs]mY2zw`nKDC]j%KXK 'P@$I=Y%C%gx'$!V(ekڤք'Qt!x7xbJ7 o߼W_y|nʒ;Fido/_1z/L?>o_;9:33`=—S,FĔ觑@)R8elmEv|!ո/,Ә%qh|'1:`ij.̳u'k CZ^WcK0'E8S߱sˮdΙ`K}A"NșM1I/AeހQתGF@A~eh-QR9C 5 ~d"9 0exp<^!͸~J7䒜t L䈝c\)Ic8E&]Sf~@Aw?'r3Ȱ&2@7k}̬naWJ}N1XGVh`L%Z`=`VKb*X=z%"sI<&n| .qc:?7/N<Z*`]u-]e|aѸ¾|mH{m3CԚ .ÕnAr)[;-ݑ$$`:Ʊ>NVl%kv:Ns _OuCX=mO4m's߸d|0n;pt2e}:zOrgI( 'B='8\L`"Ǚ 4F+8JI$rՑVLvVxNN";fVYx-,JfV<+k>hP!aLfh:HHX WQXt,:JU{,Z BpB)sֻڙӇiE4(=U\.O. +x"aMB[F7x"ytѫиK-zz>F>75eo5C9Z%c7ܼ%6M2ˊ 9B" N "1(IzZ~>Yr]H+9pd\4n(Kg\V$=]B,lוDA=eX)Ly5ot e㈮bW3gp : j$/g*QjZTa!e9#i5*j5ö fE`514g{7vnO(^ ,j~V9;kvv"adV݊oTAn7jah+y^@ARhW.GMuO "/e5[s󿬅`Z'WfPt~f}kA'0z|>ܙ|Uw{@՘tAm'`4T֠2j ۣhvWwA9 ZNU+Awvhv36V`^PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!g theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] ir d 6VzL[effxf!"#%()*,.0571 !ekerfxf $&'+-/1468Tdz  ' 7 \ h n q  # / 5 8 H K [ ^ n q #&69IL\_kqv#&28=MaqiG$G$G$G$G$G$G$G$FG$G$G$G$G$FG$G$FG$G$G$G$G$FG$G$FG$G$G$G$G$FG$G$FG$G$G$G$G$FG$G$G$G$8@0(  B S  ?!Check11Check12Check13Check14Check1Text22Check15Check21Check27Check33Check39Text30Text23Check16Check22Check28Check34Check40Text31Text24Check17Check23Check29Check35Check41Text32Text25Check18Check24Check30Check36Check42Text33z' ] r $ 9 L _ r ':M`'j  8 o 6 I \ o $7J]r$9jLNOQRTUWXgj~{LNOQRTUWXgj333  -ejk ) C I tt<<=>KLLNOOQRTUWXZ\NPRacgj  -ejk ) C I tt<<=>KLLNOOQRTUWXZ\NPRacgjj s`Z4hh^h`OJQJo(hHh8^8`OJQJ^Jo(hHoh^`OJ QJ o(hHh ^ `OJQJo(hHh ^ `OJQJ^Jo(hHohx^x`OJ QJ o(hHhH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHj s         AUA!#A)*03B8-:<?SA!GR\cm}qo $ o"8'.81124<JKYT V?aEcdhps-s2ssC{0  )!$&,)4;i?3JOT>WghhsZ}.N!?&`)5<9N|[]`a^oCqp @#!#_(**,T224m;>JKzbh~)w $>&'*+4a6[<@AgFGkHjILcWM\|\ ]]qpss9v5y{h}   A !c2!6JbKO`PQRV``jIo7q} Q DG{#%?&&)2)HH"KPRqSTY ];fin.ooVps}d,n)) *6 7;9<=AEFJ`QXq9zh{~  U  "% & * F5 5 >6 8 A C D D G OJ J R T T U Z /c j o q r m _# $ ' ) ) 0 t1 x3 47 _9 < B /H H I O b Ol r ;~  h  g  y & 7; = mP R T rd Bg #h j   G    / ; ; v= E I P Q Q BR `R T V X Y [ a d mq t `~  ( .  / 0 > ? MA B E S jU 6X ] ^ -s Fs d#4//|13M46?FKTR-Z^abi-sDt(  $x%&(+_/F5L7=>D0STX-``pequ~vx} 4N&U'-/>?CGH9KMLVioEr2yzz~} % !G*~1l4:J@GO,W[Ybnu| n(D6=hGzIMVW^dimoqSuvx  g "#5?LU\_f#ltu(v{]  k p"#f$e&48aFJ?^DmHKNRY^ ehikmEu~  %&O'9)4b7N>?*EwEUIORT$[:`ghjpCw|J/a#,#_#+12HH^:ep{o63 "7"#q/Z788J{RVrW\}^|k   ! 8* c+ 2 d6 *S "W X "b 'e | } !!!,%!{,![2!{4!6!7!@!6F!I!J!N!RT!jW!`X![!_!Hb!Qb!e!gm!x!E{!"" """<"j#"-"-"T/"7"7"?"I"\I"Q" V"Z"`"Dg"|h"h"j" o"x"~"K## #X#E## #&#2)#)#*#2#h:# ;#~=#oA#C#D#N#sP#8R#AU#{_#e#m#Lw#w#0$A $b $$:!$*$*$o+$V-$i-$.0$4$E$I$S$&h$p${$|$]}$y}$^%p%%$%&%,%1%2%x6%6%[7%<%O%R%S%S%e%g%Sq%Ps%v%w%}%~%%9& &P&k&&&&&&"&V$&1&3&6&>&H&oM&`&ca&"m&''''''i%' )'0'x4'4'x='>'yH'gN'V'W'Y']'^'c'g'h'h'i'`s'cu'nu'x'U}'''((O(((3(@(($()(2(L5(i7(=(?(I(M(O(T(3Z(jZ(+[(](R^(nu(v(w(()))))))!)*).)Z/)0)U2)N4)4););).B)K)T)[)6c)og){)|))**{**s * **d* *o*{ *6*7*E8*;*;*e<*A*B*J*T*T*]*i`*uf*Qs*z**++ +G +]++[+G+ +F&+'+@+C+tL+OM+N+b+pd+h+|+}+C~+,,,g,a,,(,+,m=,@,0E,E,WN,JQ,Q,)R,T,JU,WV,\,\,`b,b,8n,n,p,s,|~,-@-- -----S!-!-$-%-n&-x/-0-]2-3-R6-c>-F-%G-K-jL-W-a-e-$k-l-p-$r-Bv-x-p-.,. ...y..8...#.P$.H&./.8.B=.:C.I.K.R.X[.vc.d.j.*n.$u.u.}./%///& /0 /"/q$/$/&/&/r'/./1/y4/:/?>/wO/U/ [/]/b/sd/j/p/1/$00 0 0090&0D'0-0004090ZH0J0|_0g0Tl0n0*s0!w0y0k|011 1l1 1'"1&1*1.10171TC1C1G17N1S1U1zk1?l14n1222F22V22w2M22"2.2K2T2Z2 [2l2o2u2*3J3Q3w3o3(.3673=3#H3mN3Q3T3X3+[38[3\]3C`3y34M4n 4 44v44&4A444j44!4#4%40424A4!G4W4x^4^4e4g4Pi4n4np4~r4is4u4v4x4V 5 5}5505%5>5$5*5+515D35V45l55K7595<5}>5I5pJ5XQ5W5g5mk5n5p5|5/61 6N6J&6o&6-6.6@6rB6M6N6O6W6X6[6n_6a6h6h6j6\n6Gv6}677777727>7E7M7O7.S7U7W7X7X7Y7]7=_7Ma7o72q7v7Qy7M|738$8&8J*8.81878,?8HD8F8K8N8P8OU8F\8z_8Vf83h8w8|8|899999A9*9395959@:9@9A9Y`9`9g9i9[j9k9q9x9::D:::#:27:8:=:#E:F:H:MJ::M:M:N:Xd:d:Yh:i:kl:v:}:P~::e;;`;;;;;&;);J/;4;:;'A;!N; O;0Q;Q;]X;^;>e >>>>>!>H#>9>>> @>cP>[S>f>Ri>k>r>_u>>y>y>{{>{>?c? ?T ???D??? ?X??#?6?6?9?&A?kC?C?I?N?IS?zY?\?e?EEEE%E'E1E0;E?Eq@E!AEREWEWEaElE^mEmEoEsE|E]~EE,FXF FF8$F'F'F-,F-F/F8F^:FBFOFUFeWFZFFbFeFlFrF wF~F~FGG+ G7 GF GGG]&G'G:G5KGzQGtUGYGYG^jG9qGzsG.uGuGH=H H#HH)HH H;!HY"H,H/H,6H7H8H CH2GHcGH)HHMHUHVH[WH)ZHeH6kHuvHxH`yH}HI: I{ IIIIXIyI"I:&I(I0Ix1I23I8IOIQIRIvXI]I`bIcIgIkIoIDrIsIuIdvIxIzI~II?J@JF J JJkJJJV J"J#J&J?J8NJTJ]JE^JaJbJTdJyfJ>hJ]hJ iJlJtJwJ}J~JKMK!K%K-,K/K5KIK$MKITKVKYKYK`KdKfKhK tK@uK0xK#LLL Lb L LLL!L#L&Lj=LBLlILNLNLOLOL]LcL@dLdLAhL}qLiuLx MPMMM9MM,M~.M7MK7M"8M.:M:MP=MN?M$DMYMZMbM}xMzMMNbNN!N%N%N'N9/N4N7NZ@N@N@NJN KN{MN=TNVN-mN nNNqNOO O)O-O.O0O9O7EOGOJOJO7NONOlOO;SOTOTO3VOYOScOcOeOWiOiO:mOznOsOuOxO_Pu"P+P;P;P.IPIPLPQP VPVPhPDhPnPrPQV QQ~QQ,Q-Q0Q4QSHSHSMSRS3\S{]SgStjSkxSTT9 TuTT T)T*T:+T,T-T5Ti8Tn?TKToSTWT)[T_TaTWcTfTlTsTtT%tTfuTJTUUgUUBUU#U(U+U,Uh.Um4UGUQU]hU)vU4|UVVV VV:"V &V81V 6V7VX;V>VEVGVKV LVuLV4MVNQV]QVUVVVWVeXV\V~^V_V aVgViVtVtVvVB~VWm WV WWmWW#W&W'WC5WA>W@WCWFWMWMWNWeRWRWSWSWWYW[W^WaWhWrW*uW~W~WX&(X1X=4X4X6Xl=X@X@XRAXEXtNXMQXVXWX YX^X6_XtdXEkXmXmXtXuXH{XYY=YqY YM YYdYYY#Y1.Y6Y8Y:Y>YAYCYJYmRYUYQVY`Y`YeYqYZZZ ZZUZZ)Z4Z 5Z9Z;Z[IZWZ\Z\Z]Z]Z_^Z_Z1dZlZvZAwZwZwZxZxZ[[ [[g[M[Y[[![d.[5[6B[J[R[9c[;f[-g[l[7o[o[r[~[\q\\\\$\\\1%\U%\%\)\M0\QB\F\tG\qI\N\U\^\`\g\j\,j\Tk\o\\]]]]]]%]Z&]c(].]1/]5]q6]9]9]=]>]E]J]M]AR]/W]`]e]Hg]ng]{]}] ^^^^^^ ^ ^(^>^?^?^W^zX^\j^9k^|^__T_T___!_&_k._2_-9_9_&;_@_MP_P_ZU_W_M\_`_b_c_ n_n_t_u__```p``$`P+`-`l2`I``L`'N`"P`e]`l]`b`b`Xc`j`t`x{`|`~`:a3 a a!a#ae*a#1at3a>aFaIaLaSa^a@aa laua\yayabb b bMbbb{bb%4bl?bFbHbNbPbVb[b\~bcc3ccchcc(c/c[2c5c%:ci:ca;cDBcDcGc0JcLcQcRc(Vcecfckcpccsc~cGdddC d!d#d%d(deBeBeEe=MeOeWebe`keneteueqyeyeffffP'fS'f-f0f3ffL@f@fBf NfVgWgegegyg-zgM{g}gh>hhhhe%h&hI'h*h-h6h08h8hy9hA:hKhNh1Rh\hdhFihqh#th~h~hiis ii.i8i|BiYOiOibij} j jjj1j3j@jCjlDjfQjWjYjQ[jajWfjr}jbk kkkk_*k/k=4ks6k?7k>kBkOk&Sk`kbk^ckckekRfkDkklk#nkpkqkzk{klll l]%l+l+l6l7lr:lyKl%PlSlFTlXlXYlnlsrlzlmmm;"m$m0&m~&m1m2mu6m8m8m@m6@mdEmPm\mamgmimmkm"rmrmsm:mn9 n>nnnnne(n7n3;n`nknYrnsntnoooooo)o!o!o *o*o>?oFoLoOoUoaogoionouoxoyo#{oO~opp pippp pp)p+pp;p3Bp,CpUp_pepfp=jp{lpPup(vpHxpq qA q>qBqql q$q'q3q5qo:q;qDqFq|Hq}IqXqZq_qaqhqqwq}qrrrrr$rv,r_3r5r8r.BrABrrIrIrRrVrXr[Zrgrkrnlrsqrb}rGssJsns ss5s.sss#s2s2sz:s5AstDsEsFsGsSsds isqsvsnzspstt~t t,t5tt-t.t5tAtHtHtjOtVtXtetvititrti|tu u uu`u$uBuSu$ug6u@uGuLuRuWudumgu^wu zu|uhvvAv{v#v'v.v50v[7v9v:v!"&+:@AFF^MNWWZ^>`ccky{7 P!#&*)*5:`?1@FTWUYZcXg7hjlmrtv#{ O))e437N8R=bBIP)RmZ]!^^al ! "Z#%&=(*/5\99J;;GNXU\ dTkipZzT}= $^'(9+ 4CYQ_R YnlUq-z8z{tB r*%,.548.9 =CC9DCDF$HEQVJtvy@{z~+P!3*+/03w@b\>_cMggsx*, "/(07BFGGIVJLLOaS[ahimpm@n> 1K_$(1)+/;00@22 67=;=@CDjFILMOV?aabfwl Ty Z!3)-29QBGMzNPu]fLny } m@/3-6W65=N2Q$[l`bn;p}G{M4)-m.FPTU [\d\qw0V!LaF&"(2;<?CMPY_ ghH{}=\6 F u)*_+[18*:NBKDEE GpN_RRT Zcejnw{!;!}#*466S=\p\\]`lrz[\m''O)))005:=;E1M|QXZgj8rr{x{v|=z 'I'+,.0579=:T;CE[Tlp|uvz} |-2%9CpG KQRaV!`lpwz{|6 H "W&;AGE2GMNSZa0fjntx{ =?#)R*0237??AwABRDIR\\,^h^aeijokyE}JQ$*b23:/;<DFFJVKcfCtzO`W))@**+1348;<>??GFN\QkFnpUs{}b]g$9% 6K?KCD3FKL[PSYX`di-oo{N v(-3@6[8!9o<AEBJM9U]^ategkpr | +b7>_@@bBQWW;hryz}~y$()u/089/K>NQzXZ_eldm'pHth{11 X}$&,8/9568D=GRIJEPPXC_cFh~nv l&'7#CEIJLRSU*Y:dms&uv{ 3%n,d;ENQRR bGfxkNpyss%v{ '|Q* %%)))1192>G=YZuaGo1tHvZ c M)*0o17!; =I JsUX-YY]_bgprpq(m:m %'=D[HeIOPTXZ``aTlmho:rv># !) .4(5P9=C0IGPTaaahGklnppw |e};j = @y%&''+F5 ;;<1??@ CJNUdmmuvMP' ++2W9e>f?XAIIPWXYZ?\>_afmr_wr|HQ s3> $/%7) 0>@LPU [hRkkrtxO> 6Q%0,4TIM4V`ZZc7mEpu yd" #,$%@4ACGIc+mo~eq, /`03<8SMZ"[y,MlB>$%1&[&+09:<LBHkIKPUW]W^{O}4P q 34S6}8;=D FNWY^beZn;5A=?BKSW1q"ux y#f3(<>B@CLc[]bb;ci{sw}~Ta J!A-.JMKQ\\gp[y{|E}~* g<--k09G;==JlPQQR"XY`8eelltwvFtc{hp")'-69b>X@MhNQ/VA[0^fjmncpvxaxXe PR!!"-015;"ACCIQsQ!_Upqy/ys  5'V/l/e2B;DLFOPoTX^1`ftghi{}!~c ')**+12308~B@DL$NORY_.`k9lnsvkw }} zx48O=FtNSW6X nHqr`s(vwxo 5 mACvF>IJJVK;QQV\]iAjSkkaqqlr~ W bD#f))+/U0=(?HuNPP~U]aw{w U%%*5z67g=W>j@HQR_Xaaqgovwyy~8?A$z&F,002K49<EoMZ_q)tyezU1JP&TTYYdqx'y .(!%n&(.P/37NCR8T>UXXZ]beuJv<~~[ #v("5),,4??pABFFtPT\bvhykz J)A,13^;?AEdKQ\S^s uv!ww{|zU '*5+.Q/ZLhPQR[T``eSht&l| (#')1,7,72.:T?/FFHMUYZBaj9l{pv{k  "#&F/H006@FKOV`bd(f&xx| q,q-345&:;?CFFZGQ:R X\S_hOit ~< ^9""+0aO7RVV0_pcs~:V z#1;?BLN[\]clp$qs.{|L`H(>0B2UUYqwv{/1o0s%*+m/^0{2:OF;GGfK'VVWX5YTYjmnGp*s%| =[n0$ &0+./:)C.CXEH/MQVUWWoarsw{D .)*118>@]@IUJO+ORp\^)_gsJu!z ) 4>E&>.m0056<MN_)dsfiGiijuntBuvEw|| (/BZPyQbhm~S b!1124=DGeNVY\_7jm%t_tvvwfy $ &K34:<?FJaKMUW ^ _agqi,qy{}<=W *1%*01 88C<)@FHIKKcLPjS_7bkl|w  /"&)j16 gknoop&} N$$$(}0m555BsJSVv\)^?eehyb y,<%&23U48]?AeEyQK\KhVisz~ [E(^/x59BKKPVWU\\dlm(qgqsuvE$,0@@JMMFOI[/]^YdffniBr tnvw0xyz|V~ Prh&&&*-4r<=E`ioxxy~IH["%%*/06CTGGPX]"__oqi= +  .f")/ 1N6q:R;;<=^BBEG"+(V._36Q9B:lBDMaaybopz~ 4"R,.2?55W68MWY\eghlWo6qwP' *3-1cM[S[$pss=|} G '+0)68MFNS'Y>Zgeh?jm5|~7 "$( ,.0=4<<d@@BDMU.X ^*_{cQhthktQ B^-,o,P/28AgBCDD6GHMQ^s`g |G|I Z O:j&H'{:;>?MSb{kkYq{a# 7N$t&@2,3<<q>BD+EiEHHmIIL[QQRUo0q=qu{|s:"/23:d=>fF>HOugm`qtjudx{|M|('0?DHOP\X[\euup gm`'/_/7N:.;@5FMX:]lrv{e '!W&27AA>RFR*UVYQ[[ghkzn[vw-[N] @ #x##)-+-189]E@FFOJ/P[Vu[bYcs1vv $ p%&@6>IJ @A FPMYO_bhimFwz= %.B24U568X;=A5D-GMf}hjo2sv  "g-r483??@zEHOUY7^bjim\|N~ )(0145;:KGMVV5Z_Z]fprwa7?$(D(:?CEzHNUAffmn | ,^!*$\%' ('+;/EIJQ}U&VXEaggilmApqqt}0  !b!#(NEEBL/MN RZ^bmk"}#4 ,%%&E)S4S56X9&:BoKb\]_fu}* 'sFl!0248>FGM9S]kPmmppp]qssVwx~"Ye9 t -239m9>?D>KKSUWh7hpswx{wvU+,, -c/M5;?BKNT.Y^bfhhxrr2s} =J%H5l<EdJKRY\^1bgNhjnpzkN"%.99:QRwh[lox: U0$3A/A%BGH3KlOAP{`pe|.P t;J !$( -e/48:/<?WNQSofk0lwx 2d$&X(n;AA!KcQT0ZkmLN@ X i@8@@Unknown G.[x Times New Roman5Symbol3. .Cx Arial9Garamond5. .[`)TahomaI. ??Arial Unicode MSC.,*{$ Calibri Light7.*{$ Calibri?= .Cx Courier New;WingdingsA$BCambria Math"hZtKaGZf K_5_5!x4>> 3qHP ?1Rh2! xxԘf 6FACULTY DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPSMaria Sullivan Doreen Baeder Oh+'0, DP p |  8FACULTY DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPSMaria SullivanNormalDoreen Baeder11Microsoft Office Word@5z @ @~@HyW_ ՜.+,00 hp  Brown University5> 7FACULTY DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS Title  !"#$%&'()*+,-./0123456789;<=>?@ABCDEFGHIJKLMNOPQRSTUVWYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry FscData :!;1TableX2WordDocument4rSummaryInformation(DocumentSummaryInformation8CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q